Wolfe Research initiates Cava stock coverage with outperform rating

Wolfe Research initiated coverage on Cava Group (NYSE:CAVA) with an outperform and $93 price target vs the current share price of $78.59 (market cap $9.15B). The company delivered LTM revenue growth of 22% and reported Q4 fiscal 2025 same-store sales and adjusted EBITDA above expectations (Truist cited same-store sales >5%), prompting multiple firms to raise targets (Stifel $90; Truist and Piper Sandler $85; Bernstein SocGen $84; UBS $75). InvestingPro notes the stock appears overvalued relative to its Fair Value despite the operational momentum.

Analysis

CAVA’s premium positioning and rollout optionality create a classic growth-at-a-premium setup where the investment case lives or dies on sustained unit economics and comp-store durability. If store-level margins prove resilient, incremental openings should lever G&A rapidly; conversely, a modest slip in comps or a slower ramp in new DMA openings will magnify downside because the valuation implicitly prices several years of flawless execution.

Second-order beneficiaries and risks are underappreciated: scale in procurement and commissary automation can drive outsized margin expansion (olive oil, specialty spreads, bowl proteins — categories with concentrated suppliers), while slower-than-expected operating leverage will disproportionately hurt suppliers who front inventory for new units and landlords who priced leases assuming steep rent recovery. Labor market tightness in suburban DMAs also stretches ramp times — longer training and slower day-one sales materially extend payback windows on new stores.

Time and catalysts are clear: the near-term (1–3 quarters) readouts that matter are comp trends and incremental margin per new store; medium term (6–18 months) is the cadence of unit openings and any shift toward franchising/licensing; long term (>18 months) is sustained national brand share versus incumbents. The primary reversal vector is execution: a 200–300bp slip in store-level margin or a slower-than-guided opening cadence would justify a double-digit downside from current multiple assumptions, while clear evidence of supply-chain-led margin expansion or a profitable franchise pipeline would re-rate the name materially higher.

Key Decisions for Investors

• Long CAVA via defined-risk call spread (buy 9–12 month calls, sell higher strike) to capture roll-out optionality with limited premium — target 2.5x downside-adjusted return if comps hold; size 2–4% PAT (portfolio allocation), unwind on single-quarter comp miss >150bps.
• Pair trade: overweight CAVA / short CMG (6–18 month horizon). Thesis: reallocation into a faster-growth premium regional player if it proves national scalability; target asymmetric 3:1 upside vs downside by sizing short to finance part of the long and cap portfolio beta exposure.
• Buy 3–6 month puts or sell covered calls into strength as a hedge if net long the name. Use puts to protect against a 10–20% drawdown from an execution miss; if selling covered calls, choose strikes ~10–15% above your cost basis and roll monthly.
• Event-driven trade: establish a small starter position ahead of quarterly prints (2% PAT), and scale to full weight only after two consecutive quarters of comp resilience and a confirmed improvement in incremental store-level margin — stop-loss and reassess if either metric reverses.